Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajiv Agarwal

Nephrology Indianapolis, IN Medical Doctor

NPI 1154386258 CMS profile 142656

1481 W 10Th St # C3004, Indianapolis, IN 46202

Open in the dashboard

General payments

$1,217,870

569 records reported · program years 2019–2025

Research payments

$294,674

Paid to them · 89 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajiv Agarwal of Indianapolis, IN is reported in the CMS Open Payments database as having received $1,217,870 across 569 general payments and $294,674 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $275,828 84
2025 Research $33,350 14
2024 General $252,650 110
2024 Research $150,794 17
2023 General $84,961 45
2023 Research $34,610 31
2022 General $224,522 118
2022 Research $75,920 27
2021 General $105,037 54
2020 General $95,322 55
2019 General $179,551 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajiv Agarwal
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Rajiv Agarwal were reported at $275,828. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Rajiv Agarwal Nephrology median Middle half National median
2019 $179,551 $236 $90–$588 $163
2020 $95,322 $135 $46–$364 $114
2021 $105,037 $202 $67–$551 $132
2022 $224,522 $242 $77–$695 $149
2023 $84,961 $254 $84–$766 $160
2024 $252,650 $300 $99–$852 $164
2025 $275,828 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $344,347 236 payments
  2. Vertex Pharmaceuticals Incorporated $267,919 108 payments
  3. Alnylam Pharmaceuticals Inc. $175,600 32 payments
  4. Akebia Therapeutics Inc $78,564 23 payments
  5. Boehringer Ingelheim International GmbH $66,795 31 payments
  6. Relypsa, Inc. $62,107 34 payments
  7. Intercept Pharmaceuticals, Inc. $59,400 6 payments
  8. Novartis Pharmaceuticals Corporation $34,770 23 payments
  9. Alexion Pharmaceuticals, Inc. $32,795 13 payments
  10. Janssen Research & Development, LLC $30,868 16 payments
  11. Other $64,703 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,103,835 343 payments
  2. Travel and Lodging $99,118 118 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,863 6 payments
  4. Food and Beverage $7,035 100 payments
  5. Education $19 2 payments
Products named General payments · program years 2019–2025
  1. Kerendia $223,074 137 payments
  2. OCALIVA $59,400 6 payments
  3. Non-Covered $50,640 19 payments
  4. Veltassa Hyperkalemia $45,639 21 payments
  5. JARDIANCE Diabetes $43,662 23 payments
  6. Veltassa Potassium Binder $24,125 13 payments
  7. INVOKANA $10,397 6 payments
  8. ULTOMIRIS $9,809 9 payments
  9. JARDIANCE Diabetes $9,350 3 payments
  10. Auryxia $9,317 3 payments
  11. Other $19,816 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $159,749 44 payments
  2. Intercept Pharmaceuticals, Inc. $110,175 41 payments
  3. Novartis Pharmaceuticals Corporation $24,750 4 payments

Records

658 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record